Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.
Dimopoulos MA, Anagnostopoulos A, Terpos E, Repoussis P, Zomas A, Katodritou E, Kyrtsonis MC, Delibasi S, Vassou A, Pouli A, Zervas K, Anagnostopoulos N, Maniatis A; Greek Myeloma Study Group. Dimopoulos MA, et al. Among authors: repoussis p. Haematologica. 2006 Feb;91(2):252-4. Haematologica. 2006. PMID: 16461313 Clinical Trial.
Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.
Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, Repoussis P, Symeonidis A, Delimpasi S, Katodritou E, Vervessou E, Michali E, Pouli A, Gika D, Vassou A, Terpos E, Anagnostopoulos N, Economopoulos T, Pangalis G. Dimopoulos MA, et al. Among authors: repoussis p. J Clin Oncol. 2007 Aug 1;25(22):3344-9. doi: 10.1200/JCO.2007.10.9926. Epub 2007 Jun 18. J Clin Oncol. 2007. PMID: 17577016 Clinical Trial.
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.
Dimopoulos MA, Pouli A, Zervas K, Grigoraki V, Symeonidis A, Repoussis P, Mitsouli C, Papanastasiou C, Margaritis D, Tokmaktsis A, Katodritou I, Kokkini G, Terpos E, Vyniou N, Tzilianos M, Chatzivassili A, Kyrtsonis MC, Panayiotidis P, Maniatis A; Greek Myeloma Study Group. Dimopoulos MA, et al. Among authors: repoussis p. Ann Oncol. 2003 Jul;14(7):1039-44. doi: 10.1093/annonc/mdg287. Ann Oncol. 2003. PMID: 12853344 Free article. Clinical Trial.
Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase.
Kastritis E, Zervas K, Repoussis P, Michali E, Katodrytou E, Zomas A, Simeonidis A, Terpos E, Delimbassi S, Vassou A, Gika D, Dimopoulos MA; Greek Myeloma Study Group. Kastritis E, et al. Among authors: repoussis p. Clin Lymphoma Myeloma. 2009 Mar;9(1):50-2. doi: 10.3816/CLM.2009.n.012. Clin Lymphoma Myeloma. 2009. PMID: 19362972
Clinical characteristics and outcome of primary systemic light-chain amyloidosis in Greece.
Michael M, Kastritis E, Delimpassi S, Michalis E, Repoussis P, Kyrtsonis MC, Katodritou E, Anagnostopoulos N, Zervas K, Dimopoulos MA; Greek Myeloma Study Group. Michael M, et al. Among authors: repoussis p. Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):56-61. doi: 10.3816/CLML.2010.n.006. Clin Lymphoma Myeloma Leuk. 2010. PMID: 20223730
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.
Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsirigotis P, Vassou A, Vervessou E, Katodritou E, Gika D, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: repoussis p. Blood. 2015 Sep 10;126(11):1392-4. doi: 10.1182/blood-2015-05-647420. Blood. 2015. PMID: 26359434 Free article. Clinical Trial. No abstract available.
No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years.
Kastritis E, Kyrtsonis MC, Hatjiharissi E, Symeonidis A, Michalis E, Repoussis P, Tsatalas K, Michael M, Sioni A, Kartasis Z, Stefanoudaki E, Voulgarelis M, Delimpasi S, Gavriatopoulou M, Koulieris E, Gika D, Vervesou E, Konstantopoulos K, Kokkini G, Zomas A, Roussou P, Anagnostopoulos N, Economopoulos T, Terpos E, Zervas K, Dimopoulos MA. Kastritis E, et al. Among authors: repoussis p. Am J Hematol. 2011 Jun;86(6):479-83. doi: 10.1002/ajh.22027. Epub 2011 Apr 20. Am J Hematol. 2011. PMID: 21509798 Free article.
Prognostication of the high-risk WM patient.
Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Michael M, Hadjiharissi E, Symeonidis A, Michalis E, Repoussis P, Tsatalas K, Sioni A, Kartasis Z, Stefanoudaki E, Voulgarelis M, Delimpasi S, Gika D, Vervesou E, Konstantopoulos K, Kokkini G, Zomas A, Roussou P, Anagnostopoulos N, Economopoulos T, Terpos E, Zervas K, Dimopoulos MA. Kastritis E, et al. Among authors: repoussis p. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):127-9. doi: 10.3816/CLML.2011.n.028. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21454212
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care.
Vassilakopoulos TP, Pangalis GA, Katsigiannis A, Papageorgiou SG, Constantinou N, Terpos E, Zorbala A, Vrakidou E, Repoussis P, Poziopoulos C, Galani Z, Dimopoulou MN, Kokoris SI, Sachanas S, Kalpadakis C, Dimitriadou EM, Siakantaris MP, Kyrtsonis MC, Dervenoulas J, Dimopoulos MA, Meletis J, Roussou P, Panayiotidis P, Beris P, Angelopoulou MK. Vassilakopoulos TP, et al. Among authors: repoussis p. Oncologist. 2012;17(2):239-49. doi: 10.1634/theoncologist.2011-0275. Epub 2012 Jan 26. Oncologist. 2012. PMID: 22282906 Free PMC article.
17 results